Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Oct 29, 2026
TickeronGET DAILY SIGNALS
West Pharmaceutical Services (WST) Delivers Strong Q3 Results with +36% EPS Growth

West Pharmaceutical Services (WST) Delivers Strong Q3 Results with +36% EPS Growth

Key Takeaways

  • Third-quarter revenue rose 8.7% year over year to $874.5 million, with organic (currency-adjusted) growth of 11.9%.
  • Adjusted earnings per share (EPS) climbed 36% to $2.66, roughly 21% above Wall Street's consensus estimate of $2.20.
  • Reported (GAAP, or Generally Accepted Accounting Principles) net income reached $214.0 million, or $3.02 per diluted share.
  • High-Value Product (HVP) Components again led the way, growing about 20% organically and representing 53% of total company sales.
  • Management raised its full-year 2026 outlook for revenue and adjusted EPS, citing strong execution.

Why These Results Matter

West Pharmaceutical Services supplies containment and delivery systems for injectable medicines to biopharmaceutical companies around the world. Its quarterly performance offers a useful window into demand trends in the injectables space, including biologics and high-growth areas such as GLP-1 treatments for diabetes and obesity. The third quarter of 2026 followed several periods of rising High-Value Product sales, so the focus was on whether that pace could hold as the contract-manufacturing side of the business navigated planned transitions. The company had also completed the divestiture of its SmartDose 3.5mL platform, giving a clearer picture of underlying operations.

Breaking Down the Reported Numbers

West reported third-quarter net sales of $874.5 million, an 8.7% increase from $804.6 million a year earlier, with organic growth of 11.9%. That topped Wall Street’s consensus estimate of about $827 million. Adjusted diluted EPS reached $2.66, up 36% from $1.96 in the prior-year quarter and $0.47 above the midpoint of the company’s own guidance. On a GAAP basis, net income rose to $214.0 million, or $3.02 per diluted share, from $140.0 million, or $1.92 per share.

The Proprietary Products segment posted $728.8 million in revenue, up 16.6% organically, driven by HVP Components that grew 20.3% organically to $466.7 million. HVP Delivery Devices advanced 26.4% organically, while Standard Products rose 3.1%. The West Vantage segment fell 6.6% organically to $145.7 million due to the expected wind-down of a continuous glucose monitoring program, though results still edged ahead of expectations. Gross margin expanded 310 basis points to 39.7%, and adjusted operating margin widened 420 basis points to 25.3%.

Management raised its full-year 2026 revenue guidance to a range of $3.41 billion to $3.42 billion and its adjusted EPS outlook to $9.38 to $9.48.

Market Reaction and Sentiment

Shares moved higher in early trading after the release. The combination of a sizable earnings beat, revenue above consensus, and a second straight upward revision to full-year guidance supported confidence in the company’s position in high-value injectable categories. Strength in HVP Components, now more than half of total sales, along with better-than-expected margin expansion, added to the positive tone. The West Vantage decline was largely anticipated because of the CGM program transition, which limited any negative reaction.

Forward Outlook and Areas to Watch

Looking ahead, the key question is whether momentum in HVP Components can continue. Management has highlighted regulatory-driven upgrades, biologics growth, and ongoing GLP-1 demand as longer-term supports, and the company added a notable number of HVP upgrade projects this year. Still, tougher year-over-year comparisons in the GLP-1 category could make growth rates harder to sustain at recent levels. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

The SmartDose 3.5mL platform divestiture will create a modeling consideration for 2027, as its removal from organic growth calculations is expected to weigh on reported growth next year. Within West Vantage, the shift toward higher-value drug-handling programs should keep near-term segment growth muted as legacy programs roll off.

On the cost side, management noted continued capacity investments to expand HVP finishing operations in Europe and the United States, while indicating that capital expenditures should stay within the targeted range. Margin trajectory, pricing contribution, and free cash flow recovery will remain important to monitor as the company works through elevated inventory and receivables levels.

Using Tickeron Tools for Research

When analyzing results like these, I often turn to Tickeron’s AI Screener to quickly filter peers and spot patterns across the sector. It helps surface relevant comparables and technical signals that complement the fundamental read, supporting a more efficient review process without replacing traditional analysis.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: WST

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


Momentum Indicator for WST turns negative, indicating new downward trend

WST saw its Momentum Indicator move below the 0 level on November 20, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 91 similar instances where the indicator turned negative. In 59 of the 91 cases, the stock moved further down in the following days. The odds of a decline are at 65%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for WST moved out of overbought territory on November 02, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 38 similar instances where the indicator moved out of overbought territory. In 19 of the 38 cases, the stock moved lower in the following days. This puts the odds of a move lower at 50%.

The Moving Average Convergence Divergence Histogram (MACD) for WST turned negative on November 17, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In 29 of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at 57%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where WST declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 57%.

WST broke above its upper Bollinger Band on October 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

Following a +1.58% 3-day Advance, the price is estimated to grow further. Considering data from situations where WST advanced for three days, in 202 of 292 cases, the price rose further within the following month. The odds of a continued upward trend are 69%.

The Aroon Indicator entered an Uptrend today. In 158 of 228 cases where WST Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 69%.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 11 (best 1 - 100 worst), indicating outstanding price growth. WST’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 48 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of 84 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.410) is normal, around the industry mean (4.964). P/E Ratio (50.802) is within average values for comparable stocks, (40.591). Projected Growth (PEG Ratio) (2.925) is also within normal values, averaging (4.143). Dividend Yield (0.003) settles around the average of (0.006) among similar stocks. P/S Ratio (7.862) is also within normal values, averaging (56.876).

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. WST’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Intuitive Surgical (NASDAQ:ISRG), Align Technology (NASDAQ:ALGN).

Industry description

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

Market Cap

The average market capitalization across the Pharmaceuticals: Other Industry is 9.78B. The market cap for tickers in the group ranges from 126 to 159.96B. ISRG holds the highest valuation in this group at 159.96B. The lowest valued company is HGYMF at 126.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Other Industry was -8%. For the same Industry, the average monthly price growth was -5%, and the average quarterly price growth was 4%. STXS experienced the highest price growth at 12%, while RGNT experienced the biggest fall at -42%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Other Industry was 21%. For the same stocks of the Industry, the average monthly volume growth was 3% and the average quarterly volume growth was -39%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 57
P/E Growth Rating: 53
Price Growth Rating: 52
SMR Rating: 81
Profit Risk Rating: 94
Seasonality Score: 18 (-100 ... +100)
Trend Prediction Engine 4
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a manufacturer of pharmaceuticals, biologics, vaccines and consumer healthcare products

Industry PharmaceuticalsOther

Industry
Medical Specialties
Address
530 Herman O. West Drive
Phone
+1 610 594-2900
Employees
10800
Web
https://www.westpharma.com
Interact to see
Advertisement
The ADR gapped lower in premarket trading and was at $335.71 in early regular-session trading, -4.65% from Thursday's close of $352.09. The move extends a global AI and chip unwind: investors are cutting crowded semiconductor bets on stretched valuations, rising sector debt, data-center opposition and Nvidia's leadership turmoil, and Nvidia's strong quarter failed to calm sentiment.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.
Meta Platforms fell from a $596.22 previous close to $583.40, a -2.15% move, with the decline built in premarket trading and held through early Friday action after Thursday's -3.27% drop. The drop was sector-driven, not company-specific: Anthropic slid roughly -6% to -10% premarket on its second trading day, reviving doubts that AI spending will generate returns, and AI-linked megacaps sold off broadly with Nasdaq 100 futures down about -1.5%.
ANT dropped from Thursday's record-debut close of $97.17 to about $88.56 in Friday premarket trading, a -8.86% move ahead of the opening bell, still above its $83 IPO price. The decline came from a broad AI and technology selloff rather than any Anthropic-specific disclosure: Nvidia and AMD traded lower premarket, index futures were sharply down, and renewed doubts over AI spending and valuations drove profit-taking after the +17.07% first-day gain.
IREN dropped -8.33% to $13.21 from Thursday's $14.41 close, with weakness building in premarket and extending through the first hour of regular trading. The decline extends a sector-wide neocloud rout: Anthropic's post-IPO slide and turmoil at Nvidia revived doubts about debt-funded AI data center spending, dragging CoreWeave and Nebius down with it; no IREN-specific news was released.